Microbiologic findings and correlations with serum tumor necrosis factor-α in patients with severe sepsis and septic shock

Journal of Infectious Diseases

Volumn 180, Issue 1, 1999, Pages 116-121

  Cohen, Jonathan ^a   Abraham, Edward ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANAEROBIC BACTERIUM; ARTICLE; BLOOD CULTURE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL TYPING TECHNIQUES; FEMALE; FUNGEMIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOLOGICAL TYPING TECHNIQUES; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032977569     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314839     Document Type: Article

References (19)

1. Vincent JL, Bihari D, Suter P, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639-44.
2. Brun-Buisson C, Doyon F, Carlet J, French Bacteremia-Sepsis Study Group. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. Am J Respir Crit Care Med 1996;154:617-24.
3. Sriskandan S, Cohen J. The pathogenesis of septic shock. J Infect 1995;30:201-6.
4. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
5. Van der Poll T, Lowry SF. Tumor necrosis in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995;3:1-12.
6. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
7. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994;180:2173-9.
8. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fe fusion protein. N Engl J Med 1996;334:1697-702.
9. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 1997;277:1531-8.
10. Knaus WA, Harrell FE, Fisher CJ Jr, et al. The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. JAMA 1993;270:1233-41.
11. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.
12. Cohen J, Carlet J, INTERSEPT Study Group. INTERSEPT: an international multicenter placebo-controlled trial of monoclonal antibody to human TNF-α in patients with sepsis. Crit Care Med 1996;24:1431-40.
13. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997;336:912-8.
14. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
15. Forni AL, Kaplan EL, Schlievert PM, Roberts RB. Clinical and microbiological characteristics of severe group A streptococcus infections and streptococcal toxic shock syndrome. Clin Infect Dis 1995;21:333-40.
16. Sveen K, Hofstad T, Milner KC. Lethality for mice and chick embryos, pyrogenicity in rabbits, and ability to gelate lysate from amoebocytes of limulus polyphemus by lipopolysaccharides from Bacteroids, Fusobacterium, and Veillonella. Acta Pathol Microbiol Scand B 1977;85B:388-96.
17. Sprung C, Finch RG, Thijs LG, Glauser MP. International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med 1996;24:1441-7.
18. Lemm G, Carlet J, Cohen J, et al. Cytokine levels in patients with the sepsis syndrome treated with a monoclonal antibody to human TNF-α (INTERSEPT trial) [abstract]. Clin Intensive Care 1995:6.68.
19. Opal SM, Cohen J. Are there fundamental differences of clinical relevance between gram-positive and gram-negative bacterial sepsis? Crit Care Med (in press).